Skip to main content
Enter the terms you wish to search for.
Select Search Option
This Site
All WCM Sites
Directory
Menu
Weill Cornell Medicine
Care
Discover
Teach
Cerchietti Research Lab
Explore this Website
Home
Research
Toggle Research menu options
Projects
Lab Team
Publications
News
Weill Cornell Medicine
Care
Discover
Teach
Home
Research
Lab Team
Publications
News
Home
Publications
Publications
Found 15 results
Author
Title
Type
Year
Filters:
Author
is
Leonard, John P
[Clear All Filters]
2023
Ruan J
,
Moskowitz AJ
,
Mehta-Shah N
,
Sokol L
,
Chen Z
,
Kotlov N
,
Nos G
,
Sorokina M
,
Maksimov V
,
Sboner A
et al.
. 2023.
Multicenter Phase 2 Study of Oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma.
.
Blood.
2022
Martin P
,
Bartlett NL
,
Chavez JC
,
Reagan JL
,
Smith SM
,
LaCasce AS
,
Jones J
,
Drew J
,
Wu C
,
Mulvey E
et al.
. 2022.
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
.
Blood. 139(8):1147-1159.
2021
Kotlov N
,
Bagaev A
,
Revuelta MV
,
Phillip JM
,
Cacciapuoti MTeresa
,
Antysheva Z
,
Svekolkin V
,
Tikhonova E
,
Miheecheva N
,
Kuzkina N
et al.
. 2021.
Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures.
.
Cancer Discov.
M Calvo-Vidal N
,
Zamponi N
,
Krumsiek J
,
Stockslager MA
,
Revuelta MV
,
Phillip JM
,
Marullo R
,
Tikhonova E
,
Kotlov N
,
Patel J
et al.
. 2021.
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.
.
Cancer Res. 81(20):5202-5216.
2018
Rutherford SC
,
Stewart EN
,
Chen Z
,
Chadburn A
,
Wehrli NE
,
van Besien K
,
Martin P
,
Furman RR
,
Leonard JP
,
Cerchietti L
. 2018.
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data
.
.
Leuk Lymphoma. 59(1):256-258.
Ruan J
,
Martin P
,
Christos P
,
Cerchietti L
,
Tam W
,
Shah B
,
Schuster SJ
,
Rodriguez A
,
Hyman D
,
Calvo-Vidal MNieves
et al.
. 2018.
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.
.
Blood. 132(19):2016-2025.
2017
Valls E
,
Lobry C
,
Geng H
,
Wang L
,
Cardenas M
,
Rivas M
,
Cerchietti L
,
Oh P
,
Yang SNing
,
Oswald E
et al.
. 2017.
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells.
.
Cancer Discov.
Rutherford SC
,
Stewart EN
,
Chen Z
,
Chadburn A
,
Wehrli NE
,
van Besien K
,
Martin P
,
Furman RR
,
Leonard JP
,
Cerchietti L
. 2017.
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.
.
Leuk Lymphoma. :1-3.
2016
Cardenas MG
,
Yu W
,
Beguelin W
,
Teater MR
,
Geng H
,
Goldstein RL
,
Oswald E
,
Hatzi K
,
Yang S-N
,
Cohen J
et al.
. 2016.
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.
.
J Clin Invest.
Marullo R
,
Rutherford SC
,
Leonard JP
,
Cerchietti L
. 2016.
Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas.
.
Cell Cycle. 15(17):2241-7.
2015
Goldstein RL
,
Yang SNing
,
Taldone T
,
Chang B
,
Gerecitano J
,
Elenitoba-Johnson K
,
Shaknovich R
,
Tam W
,
Leonard JP
,
Chiosis G
et al.
. 2015.
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.
.
J Clin Invest. 125(12):4559-71.
2013
Ruan J
,
Luo M
,
Wang C
,
Fan L
,
Yang SNing
,
Cardenas M
,
Geng H
,
Leonard JP
,
Melnick A
,
Cerchietti L
et al.
. 2013.
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes.
.
Blood. 121(26):5192-202.
Clozel T
,
Yang SN
,
Elstrom RL
,
Tam W
,
Martin P
,
Kormaksson M
,
Banerjee S
,
Vasanthakumar A
,
Culjkovic B
,
Scott DW
et al.
. 2013.
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.
.
Cancer Discov. 3(9):1002-19.
Cerchietti L
,
Leonard JP
. 2013.
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP.
.
Hematology Am Soc Hematol Educ Program. 2013:591-5.
2010
Elstrom RL
,
Martin P
,
Ostrow K
,
Barrientos J
,
Chadburn A
,
Furman R
,
Ruan J
,
Shore T
,
Schuster M
,
Cerchietti L
et al.
. 2010.
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies.
.
Clin Lymphoma Myeloma Leuk. 10(3):192-6.